Therapeutic effect of rosuvastatin on metabolic syndrome in patients with bipolar disorder

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900027173

Enrollment

Unknown

Registered

2019-11-03

Start date

2019-11-04

Completion date

Unknown

Last updated

2019-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar disorder

Interventions

1:Atorvastatin and Behavioral Interventions

2:Behavioral Interventions

Eligibility

Sex/Gender

All

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: (1) informed consent of the patient's family; (2) met the diagnostic criteria for ICD-10 bipolar disorder; (3) met the diagnostic criteria for metabolic syndrome; (4) aged 18-40 years, gender, duration not limited; (5) the type and dose of the drug to be treated are not limited.

Exclusion criteria

Exclusion criteria: (1) those with severe physical complications such as brain, liver, kidney, heart disease, hypertension, diabetes and primary hyperlipidemia; (2) pregnancy and lactation; (3) severe liver Patients with abnormal renal function; (4) severe endocrine system diseases; (5) contraindications for the use of antipsychotic drugs.

Design outcomes

Primary

Measure	Time frame
Insulin resistance;Inflammatory factor;	—

Countries

China

Contacts

Public ContactSong Zhang

Anhui Medical University

zhangsong24680@163.com+86 15695693309

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026